Background The current presence of pulmonary hypertension (PH) severely aggravates the clinical span of heart failure with preserved ejection fraction (HFPEF) leading to significant morbidity and mortality. measure the ramifications of riociguat versus placebo. The principal efficacy variable would be the differ from baseline in cardiac result at rest, assessed by right center catheter after… Continue reading Background The current presence of pulmonary hypertension (PH) severely aggravates the